Medifast director trust sells 19,089 shares. Medifast stock gains 1.67 percent

Published on 10/02/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell 27.60 percent to USD 76.38 million. Medifast stock costs EUR 10.34 on October 2, 2026 after EUR 10.17.

MED, US58470H1014, Illustration mit AI erstellt.

A trust linked to Medifast director Daniel R. Chard sold 19,089 common shares in transactions dated September 28 and September 29, 2026, according to StockTitan. MED stock was trading at EUR 10.34 at Lang & Schwarz on October 2, 2026 at 5:39 p.m. CEST, plus 1.67 percent versus the prior close of EUR 10.17.

Insider sales add a fresh signal

The trust sold 9,545 shares at a weighted-average USD 11.98 on September 28, followed by 9,544 shares at USD 11.73 on September 29. The filing states that both transactions were carried out under a Rule 10b5-1 trading plan, which places the sales within a prearranged instruction framework.

The reported transactions were connected to Daniel R. Chard, a Medifast director. After the sales, the filing listed 188,233 shares held directly and 17,678 shares held in a joint account as of September 28, 2026.

Revenue contraction meets an earnings beat

Yahoo Finance reported that Medifast generated USD 76.38 million in revenue in the second quarter of 2026, a 27.60 percent year-over-year decline. The figure nevertheless exceeded analysts' expectations by 5.10 percent, creating a mixed operating picture: the top line contracted, while the quarterly result came in ahead of the comparison standard.

Medifast's investor-relations page identifies the second-quarter 2026 earnings release and supplement as the latest quarterly materials. The company describes its business as a coach-guided metabolic health system built around personalized plans, products and independent coaches. That model gives the revenue trend and coach productivity particular importance in assessing the next reported period.

MED stock rises in late trading

At Lang & Schwarz, the EUR 10.34 reference price stood EUR 0.17 above the prior close of EUR 10.17 on October 2, 2026. The plus 1.67 percent move qualifies as a material daily gain under the reference venue, while the insider filing and revenue decline provide contrasting company-specific signals.

On the NYSE, MED was last at USD 11.64 on October 2, 2026 at 11:43 a.m. ET. The same market context showed a USD 129.5 million market capitalization, with a USD 9.22 to USD 14.15 52-week range.